EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Chimeric Therapeutics's enterprise value is A$15.32 Mil.
Chimeric Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.30 Mil. Therefore, Chimeric Therapeutics's EV-to-EBITDA for today is -1.49.
The historical rank and industry rank for Chimeric Therapeutics's EV-to-EBITDA or its related term are showing as below:
ASX:CHM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.1 Med: 0 Max: 0.42
Current: -1.57
During the past 3 years, the highest EV-to-EBITDA of Chimeric Therapeutics was 0.42. The lowest was -5.10. And the median was 0.00.
ASX:CHM's EV-to-EBITDA is ranked worse than 100% of 457
companies
in the Biotechnology industry
Industry Median: 9.79
vs ASX:CHM: -1.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Chimeric Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Chimeric Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Chimeric Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Chimeric Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chimeric Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Chimeric Therapeutics's EV-to-EBITDA falls into.
Chimeric Therapeutics's current Enterprise Value is A$15.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Chimeric Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Chimeric Therapeutics's PE Ratio for today is calculated as:
Chimeric Therapeutics's share price for today is A$0.022.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Chimeric Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.027.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Chimeric Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Chimeric Therapeutics (ASX:CHM) Business Description
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:CHM has been successfully added to your